• Mucociliary ClearanceCompleted with Results

  Denufosol in People with CF ages 2 - 4 years , protocol number Inspire 08-116

  The purpose of this study was to look at the safety and tolerability of denufosol aerosolized three times a day in pediatric CF patients 2 to 4 years of age

  • Age:

    2 Years to 4 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    2

  • Length of Participation:

    10 days

• Mucociliary ClearanceCompleted with Results

  Denufosol Inhalation Solution for People with CF and Mild Lung Disease (TIGER 1) , protocol number Inspire INS 08-108

  The purpose of this trial was to evaluate the safety and effectiveness of inhaled denufosol, a drug designed to enhance the hydration and clearance of mucus in the lungs of people with CF.

  • Age:

    5 Years to 999 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    75% or greater

  • Number of Visits:

    10

  • Length of Participation:

    50 weeks

• Mucociliary ClearanceCompleted with Results

  Denufosol Inhalation Solution in People With Mild CF Lung Disease (TIGER 2) , protocol number Inspire 08-110

  The purpose of this trial was to evaluate the safety and effectiveness of inhaled denufosol, a drug designed to enhance the hydration and clearance of mucus in the lungs of people with CF.

  • Age:

    5 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    75 to 110%

  • Number of Visits:

    6

  • Length of Participation:

    48 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.